Gilead expands HIV licensing. Gilead Sciences stock costs EUR 128.60 versus EUR 128.60
Published on 10/04/2026 at 17:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On September 16, 2026, Gilead Sciences, Inc. announced that it had expanded six royalty-free voluntary licensing agreements to include investigational once-yearly lenacapavir for HIV prevention, according to a Gilead Sciences release. The agreements cover 120 high-incidence countries and support manufacturing readiness, technology transfer and future supply planning while the Phase 3 PURPOSE 365 trial continues. At 5:42 p.m. CEST on October 4, 2026, Gilead Sciences stock cost EUR 128.60 in weekend trading at Lang & Schwarz, unchanged at 0.00 percent versus the EUR 128.60 close at Lang & Schwarz on October 2, 2026.
Weekend trading
The Lang & Schwarz price was EUR 128.60 at 5:42 p.m. CEST on October 4, 2026. The current price was unchanged versus the close of EUR 128.60 on October 2, 2026, with the reference base stated by Lang & Schwarz. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.
Licensing expansion
Gilead said the agreements extend its access planning for once-yearly lenacapavir as pre-exposure prophylaxis. The company said the treatment is investigational and has not been approved by any regulatory authority. PURPOSE 365 is an ongoing Phase 3 study evaluating the pharmacokinetics, safety and tolerability of the once-yearly injectable regimen, according to the company announcement.
Research investment
On September 8, 2026, Gilead announced the opening of a 182,000-square-foot research center at its Foster City headquarters. The company described the facility as part of its $32 billion investment in U.S. research, development and manufacturing through 2030. The center is designed to support approximately 325 employees, including 260 laboratory scientists, according to a Gilead investor release.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
